Bristol-Myers Squibb Company (BMY) Announces Specialty Pharmacy Patient Management Programs for Sprycel┬« (dasatinib) Patients  
8/15/2012 10:06:14 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka America Pharmaceutical, Inc. today announced the launch of patient management programs for Sprycel® (dasatinib) patients with a select group of specialty pharmacy providers. The specialty pharmacies include Accredo, CuraScript, Diplomat, Biologics and Avella (formerly The Apothecary Shops). The distribution of Sprycel will remain open to other specialty and retail pharmacies.